Publications

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.

Neale I. et al, (2023), mBio

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members

Jay C. et al, (2023), Frontiers in Immunology, 14

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.

Hornsby H. et al, (2023), Nature communications, 14

Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Thursz M. et al, (2023), The Journal of general virology, 104

Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.

Williams DM. et al, (2023), iScience, 26

Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Thursz M. et al, (2023), The Journal of general virology, 104

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.

Johnson SA. et al, (2023), Clinical and experimental immunology, 212, 249 - 261

Mammalian expression systems and vaccination

Carroll MW. et al, (2023), Genetically Engineered Viruses: Development and Applications, 107 - 157

Linked Mutations in the Ebola Virus Polymerase Are Associated with Organ Specific Phenotypes.

Dong X. et al, (2023), Microbiol Spectr

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC. et al, (2023), Med (N Y)

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine

Brewitz L. et al, (2023), Journal of Medicinal Chemistry

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform.

Bojkova D. et al, (2023), iScience, 26

Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea

Longet S. et al, (2023), Emerging Infectious Diseases, 29, 304 - 313

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209

Pre-clinical models to define correlates of protection for SARS-CoV-2.

Brady C. et al, (2023), Frontiers in immunology, 14

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

Donovan-Banfield I. et al, (2022), Nat Commun, 13

An introduction to the Marburg virus vaccine consortium, MARVAC.

Cross RW. et al, (2022), PLoS pathogens, 18

Avatar Mice Underscore the Role of the T Cell-Dendritic Cell Crosstalk in Ebola Virus Disease and Reveal Mechanisms of Protection in Survivors.

Rottstegge M. et al, (2022), Journal of virology

Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.

Wing PAC. et al, (2022), PLoS pathogens, 18

A prototype lateral flow assay for detection of orthopoxviruses.

Ulaeto DO. et al, (2022), The Lancet. Infectious diseases, 22, 1279 - 1280

Evolutionary implications of human transmission of monkeypox: the importance of sequencing multiple lesions.

Ulaeto DO. et al, (2022), The Lancet. Microbe, 3, e639 - e640

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

McNaughton AL. et al, (2022), JCI Insight, 7

Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.

Harvala H. et al, (2022), Transfusion, 62, 1347 - 1354

Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.

Prince T. et al, (2022), mSphere

SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients

Shankar S. et al, (2022), Journal of the American Society of Nephrology, 33, 883 - 887

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.

Guimond SE. et al, (2022), ACS central science, 8, 527 - 545

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing

Salam AP. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010289 - e0010289

Divergent trajectories of antiviral memory after SARS-CoV-2 infection

Tomic A. et al, (2022), Nature Communications, 13

Multisystem screening reveals SARS-CoV-2 in neurons of the myenteric plexus and in megakaryocytes.

Gray-Rodriguez S. et al, (2022), The Journal of pathology

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.

Ryan KA. et al, (2022), The Journal of infectious diseases, 225, 404 - 412

Advances and gaps in SARS-CoV-2 infection models.

Muñoz-Fontela C. et al, (2022), PLoS pathogens, 18

Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers

Dong X. et al, (2022), GigaScience, 11

Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.

Mellors J. et al, (2022), Frontiers in immunology, 13

Development of anti-Crimean-Congo hemorrhagic fever virus Gc and NP-specific ELISA for detection of antibodies in domestic animal sera.

Belij-Rammerstorfer S. et al, (2022), Frontiers in veterinary science, 9

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.

Longet S. et al, (2022), Frontiers in immunology, 13

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2

Huang K-YA. et al, (2022), Theranostics, 12, 1 - 17

The characterization of multiple novel paramyxoviruses highlights the diverse nature of the subfamily Orthoparamyxovirinae.

Vanmechelen B. et al, (2022), Virus evolution, 8

Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.

Gartlan C. et al, (2022), Frontiers in immunology, 13

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Tan TK. et al, (2021), Nature Communications, 12

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Lambe T. et al, (2021), Communications Biology, 4

Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic

Tipton TRW. et al, (2021), Nature Communications, 12

Quantification of type i interferon inhibition by viral proteins: Ebola virus as a case study

Locke M. et al, (2021), Viruses, 13

Severity of heterosubtypic influenza virus infection in ferrets is reduced by live attenuated influenza vaccine

Marriott AC. et al, (2021), npj Vaccines, 6

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Skelly DT. et al, (2021), Nature Communications, 12

Dose-Dependent Response to Infection with Ebola Virus in the Ferret Model and Evidence of Viral Evolution in the Eye.

Watson RJ. et al, (2021), Journal of virology, 95

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Payne RP. et al, (2021), Cell, 184, 5699 - 5714.e11

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.

Huo J. et al, (2021), Nature communications, 12

Cookies on this website

Publications